Core Scientific, Inc.
Core Scientific, Inc. (CORZ) Financial Performance & Income Statement Overview
Explore the financials of Core Scientific, Inc. (CORZ), including yearly and quarterly data on income, cash flow, and balance sheets.
Core Scientific, Inc. (CORZ) Income Statement & Financial Overview
Analyze Core Scientific, Inc.’s CORZ earnings with segmented quarterly and yearly financial statement figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $79.53M | $94.92M | $95.35M | $141.10M |
| Cost of Revenue | $71.31M | $90.16M | $95.51M | $102.28M |
| Gross Profit | $8.21M | $4.76M | -$156000.00 | $38.82M |
| Gross Profit Ratio | $0.10 | $0.05 | -$0.002 | $0.28 |
| R&D Expenses | $0.00 | $5.02M | $2.84M | $2.17M |
| SG&A Expenses | $40.12M | $38.58M | $37.51M | $29.21M |
| Operating Expenses | $40.12M | $44.55M | $40.35M | $31.38M |
| Total Costs & Expenses | $111.43M | $133.75M | $135.86M | $133.67M |
| Interest Income | $0.00 | $0.00 | $0.00 | $14.78M |
| Interest Expense | -$2.19M | $1.14M | $7.07M | $0.00 |
| Depreciation & Amortization | $0.00 | $29.16M | $28.69M | $31.46M |
| EBITDA | -$42.60M | -$234.88M | -$419.36M | -$758.52M |
| EBITDA Ratio | -$0.54 | -$2.47 | -$4.40 | -$5.38 |
| Operating Income | -$42.60M | -$39.78M | -$41.22M | $7.43M |
| Operating Income Ratio | -$0.54 | -$0.42 | -$0.43 | $0.05 |
| Other Income/Expenses (Net) | $623.49M | -$225.38M | -$413.91M | -$812.19M |
| Income Before Tax | $580.90M | -$265.17M | -$455.13M | -$804.75M |
| Income Before Tax Ratio | $7.30 | -$2.79 | -$4.77 | -$5.70 |
| Income Tax Expense | $205000.00 | $375000.00 | $134000.00 | $144000.00 |
| Net Income | $580.69M | -$265.54M | -$455.26M | -$804.90M |
| Net Income Ratio | $7.30 | -$2.80 | -$4.77 | -$5.70 |
| EPS | $1.44 | -$0.87 | -$1.56 | -$4.51 |
| Diluted EPS | $1.25 | -$0.60 | -$1.56 | -$2.80 |
| Weighted Avg Shares Outstanding | $315.19M | $306.15M | $292.49M | $178.50M |
| Weighted Avg Shares Outstanding (Diluted) | $363.31M | $306.15M | $292.49M | $287.51M |
Over the past four quarters, Core Scientific, Inc. demonstrated steady revenue growth, increasing from $141.10M in Q2 2024 to $79.53M in Q1 2025. Operating income reached -$42.60M in Q1 2025, maintaining a consistent -54% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at -$42.60M, reflecting operational efficiency. Net income rose to $580.69M, with EPS at $1.44. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan